Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLC

Kawaguchi, Tomoya; Takada, Minoru; Kubo, Akihito; Matsumura, Akira; Fukai, Shimao; Tamura, Atsuhisa; Saito, Ryusei; Maruyama, Yosihito; Kawahara, Mutsuto; Ou, Sai‐Hong Ignatius

doi:10.1097/jto.0b013e3181d2dcd9

Cited by 263 publications

(203 citation statements)

References 25 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…Patient performance status was an important prognostic factor in all stages of NSCLC, which is concordant with studies by Sculier et al [22] and Kawaguchi et al [23].…”

Section: Nsclcsupporting

confidence: 91%

Gender-Related Survival in Different Stages of Lung Cancer—A Population Study over 20 Years

Svensson¹,

Ewers²,

Ohlsson³

et al. 2014

OJIM

View full text Add to dashboard Cite

Introduction: Tumour stage is the most important prognostic factor in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The aim of this study was to evaluate if female gender was a prognostic factor in different tumour stages in relation to histology and given therapy. Methods: From 1989-2008, 1497 patients in eastern Scania, in southern Sweden with 202,000 inhabitants, were referred and prospectively registered. Tumour stage, performance status, lung cancer type and primary therapy were registered. Results: In NSCLC, female patients in stages 1 and 2 who were treated with surgery had a better 5-year survival rate (79.4%), compared to males (60.6%; p = 0.0004). Female patients in stage 3 with active therapy (surgery and/or radiotherapy and/or chemotherapy) had a better 5-year survival than males (20.6% vs. 10.5%, respectively, p = 0.0006). Female patients with adenocarcinoma were favourable in stages 1-3. In stage 4, there was no survival difference between females and males. In SCLC, females with limited disease (LD) and active therapy (chemotherapy ± radiotherapy ± surgery) had a higher 5-year survival rate (28%) than males (5.6%); p = 0.001. Females with extensive disease (ED) and active therapy (chemotherapy ± radiotherapy) had a better 5-year survival (3.9%) compared to males (0.7%); p = 0.023. In multivariate analyses, patient performance status at diagnosis was also an independent prognostic factor in all tumour stages of lung cancer. Conclusions: This population-based study corroborates a female survival advantage in NSCLC stages 1-3, but not in metastatic stage 4, and this is also demonstrated for the adenocarcinoma subgroup. The study also confirms better prognosis in females with SCLC in both LD and ED. The study also demonstrates the importance of patient performance status as a prognostic factor in all stages of lung cancer.

show abstract

“…Patient performance status was an important prognostic factor in all stages of NSCLC, which is concordant with studies by Sculier et al [22] and Kawaguchi et al [23].…”

Section: Nsclcsupporting

confidence: 91%

Gender-Related Survival in Different Stages of Lung Cancer—A Population Study over 20 Years

Svensson¹,

Ewers²,

Ohlsson³

et al. 2014

OJIM

View full text Add to dashboard Cite

show abstract

“…Despite the many scientific efforts made to this desperate illness, only both performance status (PS) and tumour staging has been accepted as independent prognostic factors for nonsmall cell lung cancer (NSCLC). 1 There is no doubt that new prognostic and predictive factors are needed. Cancer patients with similar histopathologies and clinical features might have different prognosis and response to the treatments.…”

Section: Introductionmentioning

confidence: 99%

The Relationship Between Common EGFR, BRAF, KRAS Mutations and Prognosis in Advanced Stage Non-Small Cell Lung Cancer with Response to the Treatment in Turkey.

Doğan¹

2014

UHOD

View full text Add to dashboard Cite

The aim of the study was to evaluate EGFR (exon 19 deletion, exon 21 L858R point mutation), KRAS and braf mutation rates besides their relationship with survival and response to the treatment in non small cell lung cancer (NSCLC). We evaluated 513 NSCLC patients followed-up between January 2004 and November 2009 according to our registration data, retrospectively. Only 42 advanced stage NSCLC patients had enough tumor tissue material in paraffin blocks for all mutation analysis. The patients were evaluated retrospectively for clinicopathological features, EGFR, KRAS and BRAF mutations, erlotinib treatment, time to progression (TTP) and overall survival (OS).Mutation rates were as 7.14% (two patients) for EGFR exon 19 deletion; 4.76% (one patient)for KRAS codon 61 deletion and 2.38% for BRAF V600E mutation. They had neither EGFR exon 21 point mutation nor different mutations together. Median follow-up was 26 months (5-83) for all patients. It was 43 months (23-83) for the patients who had erlotinib and 23 months (5-61) for those who did not. Ten (23.8%) patients had erlotinib. There was significant survival difference between the patients taking erlotinib and the others (28 ± 3 months versus 15 ± 4 months, p= 0.05). TTP and OS were longer in the patients who had mutations, however the difference was not significant (p= 0.119 and p= 0.06). To our knowledge, this is the first study evaluating EGFR, KRAS and BRAF mutations in advanced stage NSCLC in Turkey .

show abstract

“…Liao et al [16] reported that whole-body measurement of MTV successfully predicted survival in stage IV NSCLC. Clinical variables including TNM staging system, histological type, performance status, and smoking status are known to predict the prognosis of NSCLC patients [19][20][21]. This study aimed to further stratify patients with stage IV NSCLC by measuring MTV using F-18 FDG PET/CT and compared it with various clinical factors for prediction of prognosis.…”

Section: Introductionmentioning

confidence: 99%

Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer

Yoo

Kim

Chong

et al. 2012

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose This study aimed to further stratify prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) by measuring their metabolic tumor volume (MTV) using F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Materials and MethodsThe subjects of this retrospective study were 57 patients with stage IV NSCLC. MTV, total lesion glycolysis (TLG), and maximum standardized uptake value (SUVmax) were measured on F-18 FDG PET/CT in both the primary lung lesion as well as metastatic lesions in torso. Optimal cutoff values of PET parameters were measured by receiver operating characteristic (ROC) curve analysis. Kaplan-Meier survival curves were used for evaluation of progression-free survival (PFS). The univariate and multivariate Cox proportional hazards models were used to select the significant prognostic factors. Results Univariate analysis showed that both MTV and TLG of primary lung lesion (MTV-lung and TLG-lung) were significant factors for prediction of PFS (P<0.001, P00.038, respectively). Patients showing lower values of MTV-lung and TLG-lung than the cutoff values had significantly longer mean PFS than those with higher values. Hazard ratios (95 % confidence interval) of MTV-lung and

show abstract

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLC

Abstract: PS and smoking status are independent prognostic factors for OS in NSCLC.

Cited by 263 publications

References 25 publications

Gender-Related Survival in Different Stages of Lung Cancer—A Population Study over 20 Years

Gender-Related Survival in Different Stages of Lung Cancer—A Population Study over 20 Years

The Relationship Between Common EGFR, BRAF, KRAS Mutations and Prognosis in Advanced Stage Non-Small Cell Lung Cancer with Response to the Treatment in Turkey.

Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About